Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:ARQT

Arcutis Biotherapeutics Q3 2026 Earnings Date & Estimates

Arcutis Biotherapeutics logo
$31.81 +0.61 (+1.96%)
Closing price 04:00 PM Eastern
Extended Trading
$31.22 -0.59 (-1.85%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcutis Biotherapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arcutis Biotherapeutics in Q3 2026

Arcutis Biotherapeutics is expected to post earnings of $0.18 per share on revenue of $142.59 million. In the same quarter a year earlier Arcutis Biotherapeutics reported $0.06 per share on revenue of $99.22 million. Arcutis Biotherapeutics last reported on August 5, 2026, posting $0.11 per share and beating the $0.0551 consensus estimate. Arcutis Biotherapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.18
Expected Revenue
$142.59 million
Prior-Year EPS
$0.06
Prior-Year Revenue
$99.22 million
Expected EPS Growth
+200.0%
Expected Revenue Growth
+43.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.11 (Beat by +$0.0549)
Last Quarter Revenue
$129.86 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Arcutis Biotherapeutics Q3 2026 Earnings FAQ

Arcutis Biotherapeutics (NASDAQ:ARQT) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Arcutis Biotherapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arcutis Biotherapeutics to post earnings of $0.18 per share for Q3 2026.

The consensus revenue estimate for Arcutis Biotherapeutics is $142.59 million for Q3 2026.

Arcutis Biotherapeutics' next earnings date is estimated for Tuesday, October 27, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arcutis Biotherapeutics on the company's earnings history page.

Arcutis Biotherapeutics Earnings Headlines

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385871/0/en/arcutis-to-report-third-quarter-2026-financial-results-and-host-conference-call-on-november-4-2026.html
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/arcutis-biotherapeutics-arqt-gets-rating-023710673.html
Missed this in 2024? Here’s your second chance
In April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in value. Now gold has pulled back roughly 20%. Inflation is rising, the Fed is hiking rates, and government borrowing continues. Ross Givens says his long-term thesis still holds. He points to a backdoor gold play that ran 846%, 1,668%, and 1,915% in the last major cycle.tc pixel
October 26 at 1:00 AM  |  Traders Agency (Ad)
Arcutis Biotherapeutics (ARQT) Projected to Release Earnings on Tuesday
October 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31138590
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
October 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/arcutis-soars-12-guggenheim-lifts-171326281.html
Arcutis Biotherapeutics advances 11% to new 52-week high
October 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4654399-arcutis-biotherapeutics-advances-11-to-new-52-week-high
See More Arcutis Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations. The company continues to evaluate roflumilast and other potential therapies across additional dermatology indications.

Arcutis was founded in 2016 and is headquartered in Westlake Village, California. Its products are marketed primarily in the United States, where the company has built a commercial organization serving dermatology professionals and patients. Frank Watanabe serves as the company’s chief executive officer.

View Arcutis Biotherapeutics Profile
Earnings Tools